title: Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
abstract: The purpose of this study was to assess the accuracy of (18) F-fluorodeoxyglucose positron emission tomography ((18) FDG PET)-CT in detecting residual or recurrent disease after nonsurgical treatment for head and neck squamous cell carcinoma (HNSCC).
  
  
  
  We conducted a retrospective analysis of patients with oral cavity, oropharynx, larynx, hypopharynx, or cervical lymph node location of SCC treated with chemoradiotherapy. Twelve weeks posttreatment, (18) FDG PET-CT results were compared to histology if residual disease was suspected. Patients with complete response received a minimum of 24-month follow-up.
  
  
  
  Forty-seven patients were included with 40 months of median follow-up: 46 with a squamous cell carcinoma (SCC) at the primary site and 43 in the neck. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 86.7%, 90%, 76.5%, and 93.1%, respectively, at the primary site and 100%, 97.2%, 87.5%, 100%, respectively, in the neck.
  
  
  
  (18) FDG PET-CT seems effective in detecting residual disease and in predicting recurrent disease within the first 2 years of follow-up after nonsurgical treatment. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1271-E1276, 2016.
authors: Department of Otolaryngology and Skull Base Surgery, Pellegrin University Hospital, Bordeaux University, Bordeaux, France.
authors: Thomas
authors: T
authors: Sagardoy
authors: Department of Nuclear Medicine, Pellegrin University Hospital, Bordeaux University, Bordeaux, France.|Bordeaux University, INCIA, CNRS, Bordeaux, France.|CNRS, INCIA, Bordeaux, France.
authors: Philippe
authors: P
authors: Fernandez
authors: Department of Otolaryngology and Skull Base Surgery, Pellegrin University Hospital, Bordeaux University, Bordeaux, France.
authors: Abdullah
authors: A
authors: Ghafouri
authors: Department of Medical Oncology, St André University Hospital, Bordeaux University, Bordeaux, France.
authors: Laurence
authors: L
authors: Digue
authors: Department of Radiotherapy, Hôpital du Haut-Lévêque University Hospital, Bordeaux University, Pessac, France.
authors: Thibaud
authors: T
authors: Haaser
authors: Department of Nuclear Medicine, Pellegrin University Hospital, Bordeaux University, Bordeaux, France.
authors: Henri
authors: H
authors: de Clermont-Galleran
authors: Department of Otolaryngology and Skull Base Surgery, Pellegrin University Hospital, Bordeaux University, Bordeaux, France.
authors: Vincent
authors: V
authors: Castetbon
authors: Department of Otolaryngology and Skull Base Surgery, Pellegrin University Hospital, Bordeaux University, Bordeaux, France.
authors: Erwan
authors: E
authors: de Monès
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging; D000072078:Positron Emission Tomography Computed Tomography; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: 18F-fluorodeoxyglucose positron emission tomography (18FDG PET)-CT; chemoradiotherapy; head and neck squamous cell carcinoma; recurrence; treatment evaluation